No­var­tis' San­doz set­tles with No­vo Nordisk for 2024 launch of third Vic­toza gener­ic

Al­though the patents on the ac­tive in­gre­di­ent of No­vo Nordisk’s GLP-1 block­buster Vic­toza for Type 2 di­a­betes ex­pire next year, the com­pa­ny agreed in a set­tle­ment yes­ter­day that a gener­ic ver­sion of the GLP-1 from No­var­tis sub­sidiary San­doz can launch in June 2024.

“San­doz is li­censed to launch a gener­ic ver­sion of Vic­toza as of 22 June 2024, or ear­li­er un­der cer­tain cir­cum­stances,” a spokesper­son for No­vo told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER